

Nouri Neamati

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8756463/nouri-neamati-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125 papers	3,798 citations	33 h-index	59 g-index
135 ext. papers	4,648 ext. citations	7.4 avg, IF	5.84 L-index

#	Paper	IF	Citations
125	Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.. <i>Journal of Medicinal Chemistry</i> , 2022 ,	8.3	3
124	A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight. <i>ACS Pharmacology and Translational Science</i> , 2021 , 4, 624-646	5.9	8
123	Discovery of a Napabucasin PROTAC as an Effective Degradator of the E3 Ligase ZFP91. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 1626-1648	8.3	8
122	The Hydroxyquinoline Analogue YUM70 Inhibits GRP78 to Induce ER Stress-Mediated Apoptosis in Pancreatic Cancer. <i>Cancer Research</i> , 2021 , 81, 1883-1895	10.1	14
121	Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy. <i>European Journal of Medicinal Chemistry</i> , 2021 , 211, 113060	6.8	1
120	Why All the Fury over Furin?. <i>Journal of Medicinal Chemistry</i> , 2021 ,	8.3	6
119	COVID-19: Living through Another Pandemic. <i>ACS Infectious Diseases</i> , 2020 , 6, 1548-1552	5.5	29
118	Deletion of Glutathione S-Transferase Omega 1 Activates Type I Interferon Genes and Downregulates Tissue Factor. <i>Cancer Research</i> , 2020 , 80, 3692-3705	10.1	6
117	Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonists. <i>European Journal of Medicinal Chemistry</i> , 2020 , 204, 112387	6.8	3
116	Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer. <i>Theranostics</i> , 2020 , 10, 6959-6976	12.1	10
115	Inhibition of Human Immunodeficiency Virus-1 Integrase by Diketo Acid Coated Gold Nanoparticles. <i>ACS Medicinal Chemistry Letters</i> , 2020 , 11, 857-861	4.3	2
114	Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma. <i>Scientific Reports</i> , 2020 , 10, 2160	4.9	10
113	Role of the ERO1-PDI interaction in oxidative protein folding and disease. <i>Pharmacology & Therapeutics</i> , 2020 , 210, 107525	13.9	29
112	UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer. <i>Translational Oncology</i> , 2020 , 13, 100834	4.9	6
111	The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors. <i>ACS Pharmacology and Translational Science</i> , 2020 , 3, 1242-1252	5.9	5
110	Discovery of Mitochondrial Transcription Inhibitors Active in Pancreatic Cancer Cells. <i>ChemMedChem</i> , 2020 , 15, 2029-2039	3.7	0
109	Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 14276-14307	8.3	15

108	Characterization of Aminobenzylphenols as Protein Disulfide Isomerase Inhibitors in Glioblastoma Cell Lines. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 10263-10286	8.3	4
107	A Novel Redox Modulator Induces a GPX4-Mediated Cell Death That Is Dependent on Iron and Reactive Oxygen Species. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 9838-9855	8.3	15
106	Glutathione Transferase Omega-1 Regulates NLRP3 Inflammasome Activation through NEK7 Deglutathionylation. <i>Cell Reports</i> , 2019 , 29, 151-161.e5	10.6	34
105	Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy. <i>Cancer Research</i> , 2019 , 79, 2923-2932	10.1	27
104	Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design. <i>Computational Biology and Chemistry</i> , 2019 , 80, 374-383	3.6	4
103	Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes. <i>Theranostics</i> , 2019 , 9, 2282-2298	12.1	22
102	Metal-Free C-2-H Alkylation of Quinazolin-4-ones with Alkanes via Cross-Dehydrogenative Coupling. <i>Organic Letters</i> , 2019 , 21, 2365-2368	6.2	9
101	Structure-Based Design of N-(5-Phenylthiazol-2-yl)acrylamides as Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 3068-3087	8.3	10
100	Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3. <i>Theranostics</i> , 2019 , 9, 5478-5496	12.1	18
99	Design, Synthesis, and Biological Evaluation of Novel Allosteric Protein Disulfide Isomerase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 3447-3474	8.3	16
98	TAJJI: approaching experimental replicates-level accuracy for drug synergy prediction. <i>Bioinformatics</i> , 2019 , 35, 2338-2339	7.2	7
97	Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. <i>Pharmacology & Therapeutics</i> , 2019 , 195, 111-131	13.9	67
96	Synthesis, Structure-Activity Relationship Studies, and ADMET Properties of 3-Aminocyclohex-2-en-1-ones as Chemokine Receptor 2 (CXCR2) Antagonists. <i>ChemMedChem</i> , 2018 , 13, 916-930	3.7	5
95	Current Challenges and Opportunities in Treating Glioblastoma. <i>Pharmacological Reviews</i> , 2018 , 70, 412-445	14.5	309
94	Molecular Correlates of Responses to Dacomitinib and Afatinib in Bladder Cancer. <i>Bladder Cancer</i> , 2018 , 4, 77-90	1	15
93	Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 1576-1594	8.3	17
92	Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 5162-5186	8.3	27
91	Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. <i>European Urology</i> , 2018 , 74, 741-753	10.2	43

90	2,3-Dihydroquinazolin-4(1)-one as a privileged scaffold in drug design.. <i>RSC Advances</i> , 2018 , 8, 20894-20921	3.7	49
89	Discovery and Mechanistic Elucidation of a Class of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma. <i>ChemMedChem</i> , 2018 , 13, 164-177	3.7	27
88	pH-responsive selenium nanoparticles stabilized by folate-chitosan delivering doxorubicin for overcoming drug-resistant cancer cells. <i>Carbohydrate Polymers</i> , 2018 , 181, 841-850	10.3	43
87	Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines. <i>European Journal of Medicinal Chemistry</i> , 2018 , 158, 884-895	6.8	7
86	Synthesis and biological evaluation of novel 2-oxo-1,2-dihydroquinoline-4-carboxamide derivatives for the treatment of esophageal squamous cell carcinoma. <i>European Journal of Medicinal Chemistry</i> , 2018 , 155, 516-530	6.8	9
85	Synthesis, ADMET Properties, and Biological Evaluation of Benzothiazole Compounds Targeting Chemokine Receptor 2 (CXCR2). <i>ChemMedChem</i> , 2017 , 12, 1045-1054	3.7	5
84	Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. <i>Theranostics</i> , 2017 , 7, 1543-1588	12.1	294
83	Design, Synthesis, and Characterization of Brequinar Conjugates as Probes to Study DHODH Inhibition. <i>Chemistry - A European Journal</i> , 2017 , 23, 13875-13878	4.8	23
82	Tautomeric-Dependent Lactam Cycloaddition with Nitrile Oxide: Facile Synthesis of 1,2,4-Oxadiazole[4,5-]indolone Derivatives. <i>ACS Omega</i> , 2017 , 2, 3123-3134	3.9	19
81	Discovery of novel 3-hydroxypicolinamides as selective inhibitors of HIV-1 integrase-LEDGF/p75 interaction. <i>European Journal of Medicinal Chemistry</i> , 2017 , 125, 1051-1063	6.8	11
80	Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 103543-103556	3.3	27
79	Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor. <i>Nature Communications</i> , 2016 , 7, 13084	17.4	32
78	Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 5209-20	8.3	34
77	Mechanisms underlying the cytotoxicity of a novel quinazolinone-based redox modulator, QD232, in pancreatic cancer cells. <i>British Journal of Pharmacology</i> , 2015 , 172, 50-63	8.6	6
76	Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. <i>Molecular Oncology</i> , 2015 , 9, 1799-814	7.9	37
75	Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models. <i>Journal of Chemical Information and Modeling</i> , 2015 , 55, 1720-38	6.1	21
74	Membrane permeable lipophilic cations as mitochondrial directing groups. <i>Current Topics in Medicinal Chemistry</i> , 2015 , 15, 745-66	3	32
73	Alteration of select gene expression patterns in individuals infected with HIV-1. <i>Journal of Medical Virology</i> , 2014 , 86, 678-86	19.7	6

72	Protein disulfide isomerase: a promising target for cancer therapy. <i>Drug Discovery Today</i> , 2014 , 19, 222-408	408	158
71	Diketoacid chelating ligands as dual inhibitors of HIV-1 integration process. <i>European Journal of Medicinal Chemistry</i> , 2014 , 78, 425-30	6.8	12
70	Design and discovery of flavonoid-based HIV-1 integrase inhibitors targeting both the active site and the interaction with LEDGF/p75. <i>Bioorganic and Medicinal Chemistry</i> , 2014 , 22, 3146-58	3.4	39
69	Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase. <i>Bioorganic and Medicinal Chemistry</i> , 2014 , 22, 5446-53	3.4	14
68	Pyrimidine-based compounds modulate CXCR2-mediated signaling and receptor turnover. <i>Molecular Pharmaceutics</i> , 2014 , 11, 2431-41	5.6	12
67	Design and discovery of novel quinazolinone-based redox modulators as therapies for pancreatic cancer. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014 , 1840, 332-43	4	24
66	A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling. <i>British Journal of Pharmacology</i> , 2014 , 171, 1551-65	8.6	10
65	Selective binding of naphthoquinone derivatives to serum albumin proteins and their effects on cytotoxicity. <i>Chemico-Biological Interactions</i> , 2014 , 214, 10-7	5	12
64	In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. <i>Journal of the American Chemical Society</i> , 2013 , 135, 11623-11633	16.4	177
63	Discovery of a novel 5-carbonyl-1H-imidazole-4-carboxamide class of inhibitors of the HIV-1 integrase-LEDGF/p75 interaction. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 5963-72	3.4	31
62	gp130: a promising drug target for cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 1303-28	328	43
61	A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 9170-9	8.3	97
60	Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor/p75 (IN-LEDGF/p75) interaction. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 2311-22	8.3	52
59	Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 937-49	6.1	73
58	Viral enzymes containing magnesium: Metal binding as a successful strategy in drug design. <i>Coordination Chemistry Reviews</i> , 2012 , 256, 3063-3086	23.2	44
57	Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 6645-68	8.3	149
56	Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 16348-53	11.5	149
55	Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 8407-20	8.3	39

54	Discovery and preclinical evaluation of a novel class of cytotoxic propynoic acid carbamoyl methyl amides (PACMAs). <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 2902-14	8.3	22
53	Insights into HIV-1 Integrase-DNA Interactions 2011 , 83-94		
52	Azaindole Hydroxamic Acids are HIV-1 Integrase Inhibitors 2011 , 265-274		
51	Allosteric inhibitor development targeting HIV-1 integrase. <i>ChemMedChem</i> , 2011 , 6, 228-41	3.7	49
50	Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: a scaffold hopping approach using salicylate and catechol groups. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 4935-52	3.4	40
49	Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery. <i>Cancer Biology and Therapy</i> , 2010 , 9, 192-203	4.6	31
48	Design and synthesis of novel nitrogen-containing polyhydroxylated aromatics as HIV-1 integrase inhibitors from caffeic acid phenethyl ester. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009 , 19, 4574-8	2.9	22
47	Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. <i>Retrovirology</i> , 2009 , 6, 25	3.6	117
46	Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu. <i>Expert Opinion on Therapeutic Patents</i> , 2007 , 17, 83-102	6.8	8
45	Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy. <i>Trends in Pharmacological Sciences</i> , 2007 , 28, 526-35	13.2	62
44	Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors. <i>ChemMedChem</i> , 2006 , 1, 238-44	3.7	12
43	Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 10080-5	11.5	93
42	Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 111-20	8.3	91
41	Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 8009-15	8.3	46
40	Design and synthesis of novel indole beta-diketo acid derivatives as HIV-1 integrase inhibitors. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 5298-310	8.3	112
39	Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 2561-73	8.3	168
38	Dipyrimidine-based inhibitors of HIV-1 integrase. <i>Expert Opinion on Investigational Drugs</i> , 2003 , 12, 289-92	3.9	10
37	Preparation of DNA-protein complexes suitable for spectroscopic analysis. <i>Methods in Molecular Medicine</i> , 2003 , 85, 185-202		1

36	Structural investigation of 3,5-disubstituted isoxazoles by ¹ H-nuclear magnetic resonance. <i>Journal of Heterocyclic Chemistry</i> , 2003 , 40, 1097-1102	1.9	11
35	Metal-dependent inhibition of HIV-1 integrase. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 5661-70	8.3	75
34	Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga. <i>Expert Opinion on Therapeutic Patents</i> , 2002 , 12, 709-724	6.8	69
33	New paradigms in drug design and discovery. <i>Current Topics in Medicinal Chemistry</i> , 2002 , 2, 211-27	3	45
32	A small-molecule antagonist of virion assembly. <i>Expert Opinion on Investigational Drugs</i> , 2001 , 10, 1767-70	9.9	3
31	Structure-based HIV-1 integrase inhibitor design: a future perspective. <i>Expert Opinion on Investigational Drugs</i> , 2001 , 10, 281-96	5.9	40
30	Targeting HIV-1 Integrase Zinc Binding Motif	911-936	
29	Development of Styrylquinoline Integrase Inhibitors	325-339	1
28	Slow-Onset Kinetics of HIV Integrase Inhibitors and Proposed Molecular Model	255-263	
27	Application of Protein Covalent Modification to Studying Structure and Function of HIV-1 Integrase and Its Inhibitors	415-427	
26	pp32 Is Hot	15-21	1
25	Design and Discovery of Peptide-Based HIV-1 Integrase Inhibitors	363-377	
24	Elvitegravir: Novel Quinolone HIV-1 Integrase Strand Transfer Inhibitor	231-238	
23	Structural aspects of Lentiviral Integrase-LEDGF Interaction	131-140	
22	Discovery and Development of Natural Product Inhibitors of HIV-1 Integrase	309-323	1
21	Resistance to Inhibitors of HIV-1 Integrase	477-498	
20	Cellular Cofactors of HIV Integration	105-129	1
19	Wiley Series in Drug Discovery and Development	507-508	

18	HIV Life Cycle: Targets for Anti-HIV Agents1-14	
17	Functional Interaction between Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Integrase95-103	
16	Integrase Mechanism and Function23-33	
15	Simple and Accurate In Vitro Method for Predicting Serum Protein Binding of HIV Integrase Strand Transfer Inhibitors275-286	
14	Nucleotide-Based Inhibitors of HIV Integrase379-388	1
13	Host Factors that affect Provirus Stability and Silencing141-150	
12	New Paradigm for Integrase Inhibition: Blocking Enzyme Function without Directly Targeting the Active Site457-476	
11	Computer-Aided Techniques in Design of HIV-1 Integrase Inhibitors389-413	
10	Assays for Evaluation of HIV-1 Integrase Enzymatic Activity, DNA Binding, and Cofactor Interaction151-163	1
9	HIV-1 Integrase Inhibitor Design: Overview and Historical Perspectives165-196	4
8	HIV Integrase Inhibitors: From Diketo Acids to Heterocyclic Templates: History of HIV Integrase Medicinal Chemistry at Merck West Point and Merck Rome (IRBM) Leading to Discovery of Raltegravir197-229	5
7	Conformationally Constrained Tricyclic HIV Integrase Inhibitors239-254	1
6	Role of Metals in HIV-1 Integrase Inhibitor Design287-307	3
5	Dicaffeoyltartaric Acid and Dicaffeoylquinic Acid HIV Integrase Inhibitors341-362	2
4	HIV-1 IntegraseDNA Models429-455	2
3	Structural Studies of Retroviral Integrases35-49	3
2	Retroviral Integration Target Site Selection51-65	1
1	Pleiotropic Nature of HIV-1 Integrase Mutations67-81	16

